Phase 1 Multiple Myeloma, Refractory Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1
Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
University Health Network, Toronto20 enrolled1 locationNCT07456605
Recruiting
Phase 1
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory
Washington University School of Medicine52 enrolled1 locationNCT07200089
Recruiting
Phase 1Phase 2
Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma, Refractory
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology30 enrolled1 locationNCT07477912
Recruiting
Phase 1
A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies
NeoplasmsMultiple Myeloma in RelapseMultiple Myeloma, Refractory+2 more
Technische Universität Dresden16 enrolled1 locationNCT05836896
Recruiting
Phase 1Phase 2
Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma, Refractory+1 more
Essen Biotech60 enrolled1 locationNCT07032129
Recruiting
Phase 1
A Trial of Selinexor, Ruxolitinib and Methylprednisolone
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Oncotherapeutics30 enrolled1 locationNCT06225310
Recruiting
Phase 1
LMY-920 for Treatment of Relapsed or Refractory Myeloma
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
Luminary Therapeutics30 enrolled1 locationNCT05546723